<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2130</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Проблемы приверженности больных, перенесших инфаркт миокарда, профилактическому приему ацетилсалициловой кислоты. Результаты исследования ACT</article-title><trans-title-group xml:lang="en"><trans-title>Compliance to preventive aspirin therapy in patients after acuter myocardial infarction. ACT Study results</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горбунов</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorbunov</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>руководитель лаборатории применения амбулаторных диагностических методов в профилактике хронических неинфекционных заболеваний</p></bio><email xlink:type="simple">vgorbunov@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины. Москва</institution></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine. Moscow</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2010</year></pub-date><volume>9</volume><issue>5</issue><fpage>95</fpage><lpage>101</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Горбунов В.М., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Горбунов В.М.</copyright-holder><copyright-holder xml:lang="en">Gorbunov V.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2130">https://cardiovascular.elpub.ru/jour/article/view/2130</self-uri><abstract><p>Целями исследования ACT (Aspirin underutilization and compliance in Cardiovascular diseases Treatment), выполненного в 2007-2008 гг. были определение отношения врачей к длительной профилактике малыми дозами ацетилсалициловой кислоты (АСК) и выработка мер по улучшению приверженности больных лечению с помощью специально разработанного опросника. Исследование было проведено в 18 странах Европы, Латинской Америки и Азии. Несмотря на то, что прием АСК был рекомендован &gt; 90 % больных, перенесших инфаркт миокарда, приверженность препарату была недостаточной: хорошая приверженность была отмечена лишь у 63 % больных европейцев и 54 % латиноамериканцев. Наиболее эффективными мерами по улучшению ситуации врачи, участвовавшие в исследовании, признали использование материалов, демонстрирующих профилактическую эффективность длительного приема АСК и, в особенности, формирование совместной договоренности врача и пациента по этому вопросу. Успешное практическое использование таких мер предполагает достаточную глубину познаний врача в области доказательной кардиологии и пересмотр отношений “врач-пациент” в сторону большей “демократизации”.</p></abstract><trans-abstract xml:lang="en"><p>The ACT Study (Aspirin underutilization and compliance in Cardiovascular diseases Treatment; 2007-2008) was aimed at evaluating the doctors’ views on long-term, low-dose preventive therapy with acetylsalicylic acid (ASA), as well as at developing the strategy on improving patients’ compliance via a specialised questionnaire. The study took place in 18 European, Latin American, and Asian countries. Despite the fact that ASA therapy was recommended to &gt;90 % of the patients after acute myocardial infarction, the treatment compliance was not adequate: for example, good compliance was observed only in 63 % and 54 % of European and Latin American patients, respectively. The most effective measures to increase the patients’ compliance, as reported by the participating physicians, were using the evidence on preventive effectiveness of long-term ASA therapy, and achieving a consensus between a doctor and a patient. Implementation of these measures requires good knowledge of evidence-based cardiology by the doctors, and more “democratic” doctor-patient relationship.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ацетилсалициловая кислота</kwd><kwd>инфаркт миокарда</kwd><kwd>приверженность (compliance)</kwd><kwd>исследование ACT</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acetylsalicylic acid</kwd><kwd>myocardial infarction</kwd><kwd>compliance</kwd><kwd>ACT study</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized placebocontrolled clinical trial. Ann Intern Med 1991; 114(10): 835-9.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized placebocontrolled clinical trial. Ann Intern Med 1991; 114(10): 835-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis HD, Dawis JW, Archibald DG, et al. protective effects of aspirin against acute myocardial infarction and deatg in men with unstable angina. Results of a Veterans administration Cooperative Study. N Engl J Med 1983; 309(7): 396-403.</mixed-citation><mixed-citation xml:lang="en">Lewis HD, Dawis JW, Archibald DG, et al. protective effects of aspirin against acute myocardial infarction and deatg in men with unstable angina. Results of a Veterans administration Cooperative Study. N Engl J Med 1983; 309(7): 396-403.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349-60.</mixed-citation><mixed-citation xml:lang="en">Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349-60.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 296: 316-20.</mixed-citation><mixed-citation xml:lang="en">UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 296: 316-20.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338(8779): 1345-9.</mixed-citation><mixed-citation xml:lang="en">The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338(8779): 1345-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3-е издание. Москва 2005; 1527 с.</mixed-citation><mixed-citation xml:lang="en">Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3-е издание. Москва 2005; 1527 с.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973-9.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rojas-Fernandez CH, Kephart GC, Sketris IC, Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the population-based Nova Scotia Health Survey. Can J Cardiol 1999; 15(3): 291-6.</mixed-citation><mixed-citation xml:lang="en">Rojas-Fernandez CH, Kephart GC, Sketris IC, Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the population-based Nova Scotia Health Survey. Can J Cardiol 1999; 15(3): 291-6.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">American Stroke Association/American Heart Association. Heart Disease and Stroke Statistics — 2005 Update. 2005:1-60.</mixed-citation><mixed-citation xml:lang="en">American Stroke Association/American Heart Association. Heart Disease and Stroke Statistics — 2005 Update. 2005:1-60.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Antitrombotic Trialist’s Collaboration. Collaborative metaanalysis of randomized trials of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.</mixed-citation><mixed-citation xml:lang="en">Antitrombotic Trialist’s Collaboration. Collaborative metaanalysis of randomized trials of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Becker RC, Meade TW, Berger PB, et al. American College of chest physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8-th Edition). Chest 2008; 133(6 Suppl): 776S-814.</mixed-citation><mixed-citation xml:lang="en">Becker RC, Meade TW, Berger PB, et al. American College of chest physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8-th Edition). Chest 2008; 133(6 Suppl): 776S-814.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Graham I, Atar D, Borch-Johnsen K, et al. European Society of Cardiology (ESC); European Society for Cardiovascular Prevention and Rehabilitation (EACRR); Council on Cardiovascular Nursing; et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 1): E1-40.</mixed-citation><mixed-citation xml:lang="en">Graham I, Atar D, Borch-Johnsen K, et al. European Society of Cardiology (ESC); European Society for Cardiovascular Prevention and Rehabilitation (EACRR); Council on Cardiovascular Nursing; et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 1): E1-40.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 373(9678): 1849-60.</mixed-citation><mixed-citation xml:lang="en">US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 373(9678): 1849-60.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Burwen DR, Galusha DH, Lewis JM, et al. National and State trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163(12): 1430-9.</mixed-citation><mixed-citation xml:lang="en">Burwen DR, Galusha DH, Lewis JM, et al. National and State trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163(12): 1430-9.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zaninelli A, Kaufholz C, Scwappach D. Physicians attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. Postgraduate Medicine 2009; 2(6): 44-53.</mixed-citation><mixed-citation xml:lang="en">Zaninelli A, Kaufholz C, Scwappach D. Physicians attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. Postgraduate Medicine 2009; 2(6): 44-53.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996; 124(3): 292-8.</mixed-citation><mixed-citation xml:lang="en">Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996; 124(3): 292-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147(2): 293-300.</mixed-citation><mixed-citation xml:lang="en">Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147(2): 293-300.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia Rodriguez LA, Patrignani P, Gonzalez-Perez A. Risk of myocardial infarction persisting after discontinuation of nonsteroidal anti-inflammatory drugs in the general population. J Thromb Haemost 2009; 7: 892-4.</mixed-citation><mixed-citation xml:lang="en">Garcia Rodriguez LA, Patrignani P, Gonzalez-Perez A. Risk of myocardial infarction persisting after discontinuation of nonsteroidal anti-inflammatory drugs in the general population. J Thromb Haemost 2009; 7: 892-4.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task Force on ACEinhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.</mixed-citation><mixed-citation xml:lang="en">Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task Force on ACEinhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Рафальский В.В., Крикова А.В., Багликов А.Н. Особенности клинической фармакологии ацетилсалициловой кислоты как антитромботического препарата. Кардиоваск тер профил 2009; 8(7): 1-6.</mixed-citation><mixed-citation xml:lang="en">Рафальский В.В., Крикова А.В., Багликов А.Н. Особенности клинической фармакологии ацетилсалициловой кислоты как антитромботического препарата. Кардиоваск тер профил 2009; 8(7): 1-6.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Аверков О.В. Ацетилсалициловая кислота как лекарственное средство: какие лекарственные формы препарата предпочтительнее с позиций доказательной медицины? Кардиоваск тер профил 2010; 2: 61-8.</mixed-citation><mixed-citation xml:lang="en">Аверков О.В. Ацетилсалициловая кислота как лекарственное средство: какие лекарственные формы препарата предпочтительнее с позиций доказательной медицины? Кардиоваск тер профил 2010; 2: 61-8.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Васюк Ю.А., Шальнова С.А., Школьник Е.Л., Куликов К.Г. Исследование ПРИМА: триметазидин с модифицированным высвобождением действующего вещества в лечении пациентов со стабильной стенокардией, перенесших инфаркт миокарда. Эпидемиологический и клинический этапы. Кардиология 2008; 12: 10-3.</mixed-citation><mixed-citation xml:lang="en">Васюк Ю.А., Шальнова С.А., Школьник Е.Л., Куликов К.Г. Исследование ПРИМА: триметазидин с модифицированным высвобождением действующего вещества в лечении пациентов со стабильной стенокардией, перенесших инфаркт миокарда. Эпидемиологический и клинический этапы. Кардиология 2008; 12: 10-3.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Оганисян Н.С., Дмитриева Н.А., Кочетков А.М., Марцевич С.Ю. Особенности диагностики и вторичной профилактики артериальной гипертонии по результатам опроса врачей. РФК 2006; 2: 37-42.</mixed-citation><mixed-citation xml:lang="en">Оганисян Н.С., Дмитриева Н.А., Кочетков А.М., Марцевич С.Ю. Особенности диагностики и вторичной профилактики артериальной гипертонии по результатам опроса врачей. РФК 2006; 2: 37-42.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
